149 filings
6-K
PRQR
ProQR Therapeutics N.V
9 May 24
Current report (foreign)
7:02am
6-K
PRQR
ProQR Therapeutics N.V
8 May 24
ProQR Announces Preclinical Proof of Concept Data for AX-0810 Axiomer™ RNA Editing Program Targeting NTCP for Cholestatic Diseases
8:07am
6-K
PRQR
ProQR Therapeutics N.V
23 Apr 24
Current report (foreign)
7:06am
6-K
PRQR
ProQR Therapeutics N.V
19 Apr 24
ProQR Achieves Successful Defense of New Challenge to its Axiomer™ IP Portfolio
7:06am
6-K
PRQR
ProQR Therapeutics N.V
13 Mar 24
ProQR Announces Year End 2023 Operating and Financial Results
7:10am
6-K
1n2op6mhrj
15 Feb 24
ProQR Announces Japanese Axiomer™ Patent Upheld Following Opposition Against Its Leading IP Estate for ADAR-mediated RNA Editing
7:46am
6-K
zwgw437qgr1r9fcjk
19 Jan 24
ProQR Highlights New Platform Data from Presentation on Axiomer™ RNA Editing Technology at Deaminet 2024
7:08am
6-K
09i ybz2vvju75qma0r1
5 Jan 24
Current report (foreign)
7:08am
6-K
d1to vihxdv
8 Dec 23
ProQR Therapeutics Announces Transaction Completed for Théa to Acquire Sepofarsen and Ultevursen Ophthalmic Assets
7:37am
6-K
mx0nq1dl om
7 Nov 23
Current report (foreign)
10:00am
6-K
f46h1d8 tzbgfs3x4w
27 Sep 23
ProQR Therapeutics Provides Update on Ophthalmic Assets
7:06am
6-K
mzbei6a39m2xxpuo
3 Aug 23
Current report (foreign)
7:15am
6-K
9yyv p0rwe2f
1 Aug 23
ProQR Therapeutics and Laboratoires Théa Announce Agreement for Théa to Acquire ProQR’s Sepofarsen and Ultevursen Ophthalmic Assets
7:15am
6-K
dd589n8qoier
17 May 23
Current report (foreign)
4:05pm
6-K
k4omq
16 May 23
Current report (foreign)
7:15am
6-K
oxgi31e20uwd8
18 Apr 23
Current report (foreign)
8:05am
6-K
4ogb22h
29 Mar 23
ProQR Announces Initial Pipeline Targets and Highlights Axiomer® RNA Editing Platform Technology at R&D Event
8:07am
6-K
okez5q3ddvb6agexb1
10 Mar 23
Current report (foreign)
4:10pm
6-K
7y8 mj5fzx
23 Dec 22
Current report (foreign)
7:10am
6-K
cqlprv
9 Nov 22
Current report (foreign)
7:03am